The potential of 15N metabolic labeling for schizophrenia research

Authors

  • Michaela D. Filiou Instituto Max Planck de Psiquiatria; Proteômica e Biomarcadores

DOI:

https://doi.org/10.1590/S0101-60832012005000006

Keywords:

Schizophrenia, quantitative proteomics, 15N metabolic labeling, biomarker, G72

Abstract

Psychiatric research is in need of non-hypothesis driven approaches to unravel the neurobiological underpinnings and identify molecular biomarkers for psychiatric disorders. Proteomics methodologies constitute a state-of-the-art toolbox for biomarker discovery in psychiatric research. Here we present the principle of in vivo 15N metabolic labeling for quantitative proteomics experiments and applications of this method in animal models of psychiatric phenotypes, with a particular focus on schizophrenia. Additionally we explore the potential of 15N metabolic labeling in different experimental set-ups as well as methodological considerations of 15N metabolic labeling-based quantification studies.

Downloads

Download data is not yet available.

Downloads

Published

2013-01-01

Issue

Vol. 40 No. 1 (2013)

Section

Brief Report

License

Once accepted for publication, the manuscript becomes permanent property of the Archives of Clinical Psychiatry. This copyright transfer subsumes exclusive and unlimited entitlement of the Archives of Clinical Psychiatry to publish and distribute the full contents of articles in whichever publishing medium, including press and electronic media, in Brazil and abroad.

Manuscripts are accepted with the understanding that the Editor and the editorial staff have the right to make revisions aimed at greater conciseness, clarity, and conformity with Journal style, of course without changing its content.

How to Cite

The potential of 15N metabolic labeling for schizophrenia research. (2013). Archives of Clinical Psychiatry, 40(1), 51-52. https://doi.org/10.1590/S0101-60832012005000006